Openbookopenbook
Equity
ResMed Inc.(0KW4)
USD --+0.00%
Reward72High
Risk22Low
📊75%Data
Strong 28% profit margin · Revenue growing 11% YoY
0KW4
+0.0 · +0.00%
USD · LSE
ResMed Inc. |
Quality Compounder
Market Cap:—
ℹ️
Reward Rating
72
High
Top 25% (model universe)
75% data coverage
ℹ️
Risk Rating
22
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0KW4 to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is ResMed Inc.?

develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally.

0KW4 · Verdict

Strong reward · low risk

0KW4 scores well on balance sheet and cash flow with no major weaknesses flagged in the model.

Based on 88% data coverage

0KW4 · Verdict

What’s working & what to watch

Strengths 5

  • Balance sheet99/100

    Interest covered 133.0×

  • Cash flow95/100

    32% free-cash-flow margin

  • Profitability92/100

    27% net margin · 26% ROE

  • Growth79/100

    Rev +12.9% CAGR · earnings +21.6%

  • Valuation65/100

    Above average

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is ResMed Inc.?

develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company is listed on the LSE in UK, and a P/E ratio of 0.4x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: High (72)

The scoring profile indicates a strong reward potential, driven primarily by profitability and growth. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market CapN/A
P/E Ratio0.404
Dividend Yield1.06%
52 Week High292.0742
52 Week Low212.41
Last AnnualJune
IPO DateN/A
IncorporatedUK
Shares Outstanding143M
No. of Employees10,600
IndustryN/A
ExchangeLSE
Beta0.928
CurrencyUSD
Websitewww.resmed.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.